Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicentre randomized double-blind placebo-controlled trial.

Chopra A et al.

NCBI PubMed Central · Papers · License: Open Access

computer science education

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 653487
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.